Advances in Therapy

, Volume 19, Issue 4, pp 185–193 | Cite as

Single dose of ketotifen fumarate .025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitis

  • Jack V. Greiner
  • Clifford Michaelson
  • Cecilia L. McWhirter
  • Naveed B. K. Shams
Article

Abstract

This single-masked, contralateral-eye, active-controlled allergen-challenge study compared ketotifen fumarate .025% and cromolyn sodium 4% ophthalmic solutions in the prevention of ocular itching, tearing, and redness induced by allergen challenge. After a confirmatory conjunctival provocation test (CPT), 56 patients randomly received masked study medication (placebo in one eye, cromolyn in the other eye) four times daily for 2 weeks. At visit 3, patients received one drop of ketotifen in the eye previously treated with placebo and cromolyn in the other eye. Ocular comfort was assessed 30 seconds postinstillation, and a CPT was conducted 15 minutes and 4 hours postinstillation to evaluate ocular itching, tearing, and redness. Forty-seven patients were analyzed for efficacy. At the 15-minute and 4-hour challenges, ketotifen was superior to cromolyn in preventing itching (P<.001) at all assessments and redness (ciliary, conjunctival, and episcleral) (P≤.001 ) at most assessments. Tearing scores were higher in cromolyn-treated eyes than in ketotifen-treated eyes. Patients reported greater comfort in the ketotifentreated than in the cromolyn-treated eye (P= .066). The most common adverse event was burning/stinging with cromolyn. A single dose of ketotifen was superior to a 2-week four-times-daily regimen of cromolyn in alleviating symptoms of allergic conjunctivitis in the conjunctival allergen-challenge model.

Keywords

allergic conjunctivitis clinical trial ketotifen cromolyn 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Weeke ER. Epidemiology of hay fever and perennial allergic rhinitis.Monogr Allergy. 1987;21:1–20.PubMedGoogle Scholar
  2. 2.
    Abelson, MB, George MA, Garafalo C. Differential diagnosis of ocular disorders.Ann Allergy. 1993;70:95–113.PubMedGoogle Scholar
  3. 3.
    Allansmith MR, Greiner JV, Baird RS. Number of inflammatory cells in normal conjunctiva.Am J Ophthalmol. 1978;86:250–259.PubMedGoogle Scholar
  4. 4.
    Allansmith MR. Immunology of the eye. In: Allansmith MR, ed.The Eye and Immunology. St. Louis: CV Mosby; 1982:99–115.Google Scholar
  5. 5.
    Abelson MB, Chapin MJ. Current and future topical treatments for ocular allergy.Compr Ophthalmol Update. 2000;1:303–320.Google Scholar
  6. 6.
    Collum LMT, Kilmartin DJ. Acute allergic conjunctivitis. In: Abelson MB, ed.Allergic Diseases of the Eye. Philadelphia: WB Saunders; 2000:120–127.Google Scholar
  7. 7.
    Investigator’s Brochure—Ketotifen Fumarate Eye Drops. 5th ed. Duluth, Ga: Novartis Ophthalmics; November 2001.Google Scholar
  8. 8.
    Grant SM, Goa KL, Fitton A, et al. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders.Drugs. 1990;40:412–448.PubMedCrossRefGoogle Scholar
  9. 9.
    Nabe M, Miyagawa H, Agrawal DK, et al. The effect of ketotifen on eosinophils as measured at LTC4 release and by chemotaxis.Allergy Proc. 1991;12:267–271.PubMedCrossRefGoogle Scholar
  10. 10.
    Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge—a clinical approach to studying allergic conjunctivitis.Ophthalmology. 1990;108:84–88.Google Scholar
  11. 11.
    Allansmith MR, Ross RN. Ocular allergy and mast cell stabilizers.Surv Ophthalmol. 1986;30: 229–244.PubMedCrossRefGoogle Scholar
  12. 12.
    Abelson MB, George MA, Smith LM. Evaluation of.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model.Ophthalmology. 1995;102:310–316.PubMedGoogle Scholar

Copyright information

© Health Communications Inc 2002

Authors and Affiliations

  • Jack V. Greiner
    • 1
  • Clifford Michaelson
    • 2
  • Cecilia L. McWhirter
    • 3
  • Naveed B. K. Shams
    • 3
  1. 1.Schepens Eye Research Institute and Department of OphthalmologyHarvard Medical SchoolBoston
  2. 2.Department of Ophthalmology and NeurologyBoston University School of MedicineBoston
  3. 3.Novartis Ophthalmics, Inc.Duluth

Personalised recommendations